Group 1 - In 2025, AstraZeneca's CEO Pascal Soriot received a total compensation of £17.7 million (approximately 164 million RMB), making him one of the highest-paid executives in the FTSE 100 index [1] - AstraZeneca's market capitalization exceeds $320 billion (approximately 2.2 trillion RMB), making it the highest-valued company listed on the London Stock Exchange [1] - Soriot's annual bonus reached £4.3 million in 2025, reflecting a 22% increase compared to 2024 [1] Group 2 - Novartis CEO Vas Narasimhan's compensation for 2025 is reported at 24.9 million Swiss francs (approximately 22 million RMB), marking a 30% increase from 2024 and the highest since he took office in 2018 [2] - Narasimhan's long-term incentive plan had a payout rate of 188% during the 2023-2025 period, valued at 17.3 million Swiss francs [2] - Roche's CEO Thomas Schinecker received a total compensation of 10.2 million Swiss francs (approximately 9.1 million RMB) for 2025 [2] Group 3 - Sanofi's CEO Paul Hudson received a total compensation of €10.9 million (approximately 8.8 million RMB) for 2025, but he will not receive performance bonuses for the 2026 fiscal year as he stepped down on February 17, 2025 [2] - Novo Nordisk's new CEO Maziar Mike Doustdar earned 20.7 million Danish kroner (approximately 2.2 million RMB) during his first few months in office [3] - The previous CEO Lars Fruergaard Jorgensen received nearly $20 million (approximately 137 million RMB) in total compensation for 2025, which included a severance payment of $6.82 million [3] Group 4 - The annual salaries of U.S. pharmaceutical executives for 2025 have not yet been disclosed, but historically, they tend to be higher than those of European pharmaceutical executives [3] - In 2024, Eli Lilly's CEO David Ricks had the highest salary in the global pharmaceutical industry at $29.2 million (approximately 200 million RMB) [3] - Pfizer's CEO Albert Bourla also had a significant salary of $24.6 million (approximately 170 million RMB), ranking second in the industry [3]